Caymus Purchaser, Inc. /
Cidara Therapeutics, Inc.
Merck subsidiary to acquire Cidara Therapeutics
Source for the buyer and target: Merck Sharp & Dohme LLC
For the buyer and target.
“Agreement and Plan of Merger, dated as of November 13, 2025, among Merck Sharp & Dohme LLC, Caymus Purchaser, Inc. and Cidara Therapeutics, Inc.”
Published 5 Dec 2025
Open the sourceWhat happened
Caymus Purchaser, Inc. is making an offer for all outstanding shares of Cidara Therapeutics, Inc. under a merger agreement. If the offer is successful, Cidara will become a wholly owned indirect subsidiary of Merck & Co., Inc. [01]
The filing does not state the transaction value. [01]
Who is involved, and the source
Everything on this page comes from the source below, quoted word for word.
Advisers
Target
- Fairness opinion to the targetGoldman SachsSource: SEC filing, as of 5 Dec 2025
- Fairness opinion to the targetThereafter, EvercoreSource: SEC filing, as of 5 Dec 2025
- Fairness opinion to the targetThereafter, Goldman SachsSource: SEC filing, as of 5 Dec 2025
- Financial adviser to the targetEvercoreSource: SEC filing, as of 5 Dec 2025
- Financial adviser to the targetGoldman SachsSource: SEC filing, as of 5 Dec 2025
Each adviser in its source's own words. An adviser's own announcement is labelled as one: it is not independent reporting. Advisers are not parties to the deal.
Merck subsidiary to acquire Cidara Therapeutics
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly